Adavosertib (AZD1775) with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer: An Interview With Kyle C. Cuneo, MD

Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly treated with radiation therapy, there is a need to develop alternative treatment options that can improve the efficacy of radiation, reduce tumor progression, and increase survival. In a recent study, Kyle C. Cuneo, MD, and colleagues evaluated the safety and tolerability of adavosertib (AZD1775), an inhibitor of the Wee1 ki...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.